Literature DB >> 11683247

Effect of meropenem on disposition kinetics of valproate and its metabolites in rabbits.

K Yokogawa1, S Iwashita, A Kubota, Y Sasaki, J Ishizaki, M Kawahara, R Matsushita, K Kimura, F Ichimura, K Miyamoto.   

Abstract

PURPOSE: We investigated the effect of meropenem (MEPM) on the disposition kinetics of valproate (VPA) and its metabolites in rabbits.
METHODS: Rabbits were given 75 mg/kg VPA intravenously with or without 300 mg/kg MEPM.
RESULTS: The plamsa total clearance of VPA was significantly increased to about 1.5 times the control (6.09 mL/min/kg vs. 4.28 mL/min/kg) by MEPM (P < 0.05). The values of the area under the plasma concentration-time curve (AUC) of 2-en-VPA, a product of beta-oxidation, and VPA-glucuronide (VPA-G) were significantly decreased to about 55% and 78% of the control, respectively (P < 0.05). The cumulative urinary excretions of VPA in the control and MEPM-treated groups were 0.54% and 0.62% of the dose, respectively, whereas those of VPA-G were 45.6% and 62.5%, respectively. The urinary excretion of VPA-G was significantly increased by MEPM (P < 0.05). Further, in the case of 33.8 mg/kg VPA-G administered intravenously the AUC value of VPA-G was unchanged by MEPM, whereas that of the generated VPA was significantly decreased to about half of the control.
CONCLUSIONS: The increase of the total clearance of VPA caused by MEPM appears to be a consequence of increased renal clearance of VPA-G, as well as suppression of VPA-G hydrolysis in the liver.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11683247     DOI: 10.1023/a:1013046229699

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  12 in total

1.  Lowering of plasma valproic acid concentrations during concomitant therapy with meropenem and amikacin.

Authors:  B J De Turck; M W Diltoer; P J Cornelis; V Maes; H D Spapen; F Camu; L P Huyghens
Journal:  J Antimicrob Chemother       Date:  1998-10       Impact factor: 5.790

2.  Prediction of changes in the clinical pharmacokinetics of basic drugs on the basis of octanol-water partition coefficients.

Authors:  J Ishizaki; K Yokogawa; E Nakashima; F Ichimura
Journal:  J Pharm Pharmacol       Date:  1997-08       Impact factor: 3.765

3.  Decrease in serum levels of valproic acid during treatment with a new carbapenem, panipenem/betamipron.

Authors:  K Nagai; T Shimizu; A Togo; M Takeya; Y Yokomizo; Y Sakata; T Matsuishi; H Kato
Journal:  J Antimicrob Chemother       Date:  1997-02       Impact factor: 5.790

4.  Fundamental pharmacokinetic properties of biperiden: tissue distribution and elimination in rabbits.

Authors:  K Yokogawa; E Nakashima; F Ichimura; T Yamana
Journal:  J Pharmacobiodyn       Date:  1986-04

5.  Relationships between the hepatic intrinsic clearance or blood cell-plasma partition coefficient in the rabbit and the lipophilicity of basic drugs.

Authors:  J Ishizaki; K Yokogawa; E Nakashima; F Ichimura
Journal:  J Pharm Pharmacol       Date:  1997-08       Impact factor: 3.765

Review 6.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

7.  Panipenem, a carbapenem antibiotic, enhances the glucuronidation of intravenously administered valproic acid in rats.

Authors:  N Yamamura; K Imura; H Naganuma; K Nishimura
Journal:  Drug Metab Dispos       Date:  1999-06       Impact factor: 3.922

8.  Studies on the reactivity of acyl glucuronides--III. Glucuronide-derived adducts of valproic acid and plasma protein and anti-adduct antibodies in humans.

Authors:  A M Williams; S Worrall; J de Jersey; R G Dickinson
Journal:  Biochem Pharmacol       Date:  1992-02-18       Impact factor: 5.858

Review 9.  Clinical pharmacokinetics of valproic acid--1988.

Authors:  G Zaccara; A Messori; F Moroni
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

10.  Sensitive capillary gas chromatographic-mass spectrometric method for the therapeutic drug monitoring of valproic acid and seven of its metabolites in human serum. Application of the assay for a group of pediatric epileptics.

Authors:  J Darius; F P Meyer
Journal:  J Chromatogr B Biomed Appl       Date:  1994-06-17
View more
  7 in total

1.  Observation of Clinically Relevant Drug Interaction in Chimeric Mice with Humanized Livers: The Case of Valproic Acid and Carbapenem Antibiotics.

Authors:  Eiko Suzuki; Kumiko Koyama; Daisuke Nakai; Ryoya Goda; Hiroshi Kuga; Kan Chiba
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-12       Impact factor: 2.441

2.  Valproate Interaction With Carbapenems: Review and Recommendations.

Authors:  Osama Al-Quteimat; Alla Laila
Journal:  Hosp Pharm       Date:  2019-02-22

3.  Pharmacokinetic interaction on valproic acid and recurrence of epileptic seizures during chemotherapy in an epileptic patient.

Authors:  Hiroaki Ikeda; Teruo Murakami; Mikihisa Takano; Tsuguru Usui; Kenji Kihira
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

Review 4.  Drug Interactions in Neurocritical Care.

Authors:  Brian Spoelhof; Salia Farrokh; Lucia Rivera-Lara
Journal:  Neurocrit Care       Date:  2017-10       Impact factor: 3.210

5.  Cryo-EM structure of acylpeptide hydrolase reveals substrate selection by multimerization and a multi-state serine-protease triad.

Authors:  Anna J Kiss-Szemán; Pál Stráner; Imre Jákli; Naoki Hosogi; Veronika Harmat; Dóra K Menyhárd; András Perczel
Journal:  Chem Sci       Date:  2022-05-18       Impact factor: 9.969

Review 6.  Molecular and therapeutic potential and toxicity of valproic acid.

Authors:  Sébastien Chateauvieux; Franck Morceau; Mario Dicato; Marc Diederich
Journal:  J Biomed Biotechnol       Date:  2010-07-29

7.  Unusual drug reaction between valproate sodium and meropenem.

Authors:  Hyonok Yoon; Diana H Kim
Journal:  Int J Clin Pharm       Date:  2013-03-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.